BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback